NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) Relapsed/Refractory Multiple Myeloma
Sponsor: Takeda
Listed as NCT03169361, this observational or N/A phase trial focuses on Relapsed/Refractory Multiple Myeloma and remains completed. Sponsored by Takeda, it has been updated 12 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2024 — Jul 2024 [monthly]
Completed
-
May 2022 — Jan 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Feb 2022 — May 2022 [monthly]
Active Not Recruiting
Status: Completed → Active Not Recruiting
▶ Show 7 earlier versions
-
May 2021 — Feb 2022 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Feb 2021 — May 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting
-
Aug 2018 — Jan 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jul 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Tokyo, Japan